近 5年，我国资本市场面临复杂的内外部环境，因此波动较大。在这样的市场背景下，能做到在今年来（短期）、近三年（中期）、近五年（长 期）的收益都排名居前，就显得难能可贵。 为了给读者提供一些参考，笔者根据私募排排网数据，分策略（主观多头、量化多头、多资产、期货及衍生品）梳理出了在"今年1-8月、近三 年、近五年"收益都居上游的私募产品。 （ 同一基金经理管理多只相同策略产品的，仅选收益最高的产品参与排名 ） 0 1 主观多头： 23 只私募产品短、中、长期均居前列，陈宇旗下产品在列！ 截至2025年8月底，在私募排排网有今年1-8月、近三年、近五年业绩显示的主观多头私募产品分别有1974只、1353只、760只，有鉴于此， 笔 者特梳理出了在今年 1-8月、近三年、近五年收益均居前20%的产品，共有23只 。 本文首发于公众号"私募排排网"。 （点击↑↑ 上图查看详情 ） 私募业绩在某一阶段内领先，并非难事，但要想在多个阶段内都领先，则是非常考验基金经理的投研水平和策略的持续迭代能力的。因为资本市 场的变化非常快，以A股为例，无论是市场风格还是领涨赛道，都是阶段性的轮动。 | 菲席 | 产品简称 | 产品规模 ...

Core Insights - The average return of private equity fund managers in the past year reached 21.84%, significantly outperforming the market [2] - Stock fund managers showed the highest average return of 25.52%, benefiting from the recovery of the A-share market since "924" [2][4] - Fund managers with assets under management between 0-5 billion yuan had the best performance, with average returns of 23.38% [2][4] By Strategy - Stock Strategy: 1471 managers, 2853 products, total AUM of 2330.34 billion yuan, average return of 25.52% [4] - Futures and Derivatives: 393 managers, 652 products, total AUM of 393.50 billion yuan, average return of 17.27% [4] - Multi-Asset: 297 managers, 531 products, total AUM of 476.29 billion yuan, average return of 19.32% [4] - Bond: 179 managers, 409 products, total AUM of 445.17 billion yuan, average return of 9.70% [4] - Combination Funds: 63 managers, 94 products, total AUM of 42.59 billion yuan, average return of 24.17% [4] By Company Size - Managers with over 10 billion yuan AUM: 114 managers, 586 products, total AUM of 998.51 billion yuan, average return of 20.66% [4] - Managers with 5-10 billion yuan AUM: 400 managers, 707 products, total AUM of 468.51 billion yuan, average return of 23.38% [4] - Managers with 0-5 billion yuan AUM: 1442 managers, 2104 products, total AUM of 750.51 billion yuan, average return of 22.52% [4] Top Performers - Wang Chen from Jiukun Investment topped the list among managers with over 10 billion yuan AUM [5][9] - Wu Xing from Shenzhen Kaifeng Investment led the 50-100 billion yuan category [10][11] - Chen Yu from Shennong Investment ranked first among 20-50 billion yuan managers, focusing on innovative drugs [15][19] - Sun Jie from Nengjing Investment led the 10-20 billion yuan category [22][23] - Hu Shiyuan from Wantao Private Equity topped the 5-10 billion yuan category [29][30] - Tan Guanhua from Hainan Xiangyuan Private Equity led the 0-5 billion yuan category [30][32]